Study of S-1 and Chemotherapy for Advanced Gastric Cancer
Author Information
Author(s): Rino Yasushi, Yukawa Norio, Wada Nobuyuki, Suzuki Makoto, Murakami Hitoshi, Yamada Takanobu, Nakayama Hirotaka, Yamamoto Naoto, Sato Tsutomu, Yamada Roppei, Ohshima Takashi, Masuda Munetaka, Imada Toshio
Primary Institution: Yokohama City University
Hypothesis
The study aims to evaluate the efficacy and safety of S-1 as a first-line therapy, S-1 plus cisplatin as a second-line therapy, and weekly paclitaxel as a third-line therapy for advanced gastric cancer.
Conclusion
The sequential therapy was effective for advanced gastric cancer with acceptable side effects.
Supporting Evidence
- The response rates were 33.3% for first-line, 12.5% for second-line, and 0% for third-line chemotherapy.
- The mean overall survival time was 994 days.
- No deaths were attributed to the adverse effects of the drugs.
Takeaway
Doctors tested different medicines to help people with stomach cancer, and they found a way that worked pretty well without too many bad side effects.
Methodology
The study involved 19 patients who received different chemotherapy regimens, and their responses and survival times were measured.
Limitations
The median survival time could not be calculated as many patients were still alive at the study's conclusion.
Participant Demographics
The median age was 61.3 years, with 63.2% male and 36.8% female participants.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website